Clinical Trials
Showing 11-19 results of 19 total
Blood Disorders|Cancer
New investigational drug for Follicular Lymphoma
The purpose of this study is to see if the combination of the investigational drug epcoritamab with rituximab and lenalidomide has a better response rate and...
Cancer
Investigational drug for HER2-mutated/overexpressed/amplified cancer
This study is testing whether an investigational drug will help people with advanced cancers with HER2 alterations.
Cancer
New investigational drug for treatment of Myelofibrosis
This study will evaluate the safety and effectiveness of Navetemadlin combined with an FDA approved dose of Ruxolitinib. The purpose of this Phase III study...
Cancer|Neurology|Neurosurgery
New investigational drug for newly-diagnosed MGMT unmethylated glioblastoma
The goal of this Phase 3 clinical trial is to compare the effectiveness of niraparib versus temozolomide (TMZ) in adult participants with newly-diagnosed,...
Cancer|Women's Health
Investigational drug for treatment of Triple-Negative Breast Cancer
The purpose of this study is to evaluate the safety and effectiveness of investigational drug MK2870 in combination with other approved anti-cancer...
Cancer
New investigational drug for relapsed or refractory B-cell Non-Hodgkin Lymphoma.
This study will evaluate the safety and anti-cancer activity of Loncastuximab Tesirine in combination with other anti-cancer agents.
Blood Disorders|Cancer
Study of REGN5458 plus Carfilzomib for multiple myeloma.
The primary purpose of this study is to assess the safety and tolerability an investigational drug, REGN5458, combined with the current approved standard of...
Blood Disorders|Cancer
A study for patients with aggressive B-cell non-Hodgkin lymphoma.
This study will evaluate the safety and tolerability of investigational drug IMPT-314. It will also help to determine the recommended phase 2 dosing.
Blood Disorders|Cancer
Study for patients with refractory/relapsed acute myeloid leukemia (AML).
The purpose of this study is to determine the safety and tolerability of the investigational drug BP1002 in participants who have refractory/relapsed AML...